Add to ORKGBACKGROUND: Niacin, a potent high-density lipoprotein cholesterol-raising drug, seems an attractive approach to reduce cardiac events in patients with or at risk of atherosclerotic cardiovascular disease. However, previous evidence for niacin has been challenged recently by negative outcomes in 2 large, randomized, controlled trials comparing niacin to placebo with background statin therapy. We studied the currently available evidence for the role of niacin treatment for reducing the risk of cardiovascular events in current practice. METHODS: A systematic review of randomized controlled trials in the MEDLINE, EMBASE, CINAHL, and Cochrane databases comparing niacin alone or combined with statin therapy was performed. We extracted trial level...
BACKGROUND Patients with evidence of vascular disease are at increased risk for subsequent vascular ...
Objective: Previous studies have suggested that niacin treatment raises glucose levels in patients w...
Item does not contain fulltextBACKGROUND AND AIM: High density lipoproteins (HDL) have been addresse...
BACKGROUND: Niacin, a potent high-density lipoprotein cholesterol-raising drug, seems an attractive ...
ObjectivesThis study sought to assess the efficacy of niacin for reducing cardiovascular disease (CV...
Q: Does niacin decrease cardiovascular morbidity and mortality in CVD patients? A: No. Niacin doesn'...
Niacin was the first hypolipidemic drug to significantly reduce both major cardiovascular events and...
Despite substantial risk reductions targeting low-density lipoprotein cholesterol with statins, ther...
BACKGROUND: Patients with evidence of vascular disease are at increased risk for subsequent vascular...
Background: Patients with evidence of vascular disease are at increased risk for subsequent vascular...
ObjectivesThis study sought to examine the relationship between niacin treatment, lipoproteins, and ...
Niacin has been used for more than 50 years in the treatment of cardiovascular disease, although its...
Contains fulltext : 142812.pdf (publisher's version ) (Open Access)OBJECTIVE: Niac...
International audienceBACKGROUND: Niacin as an adjunct to statin treatment to reduce cardiovascular ...
Niacin potently lowers triglycerides, mildly decreases LDL-cholesterol, and largely increases HDL-ch...
BACKGROUND Patients with evidence of vascular disease are at increased risk for subsequent vascular ...
Objective: Previous studies have suggested that niacin treatment raises glucose levels in patients w...
Item does not contain fulltextBACKGROUND AND AIM: High density lipoproteins (HDL) have been addresse...
BACKGROUND: Niacin, a potent high-density lipoprotein cholesterol-raising drug, seems an attractive ...
ObjectivesThis study sought to assess the efficacy of niacin for reducing cardiovascular disease (CV...
Q: Does niacin decrease cardiovascular morbidity and mortality in CVD patients? A: No. Niacin doesn'...
Niacin was the first hypolipidemic drug to significantly reduce both major cardiovascular events and...
Despite substantial risk reductions targeting low-density lipoprotein cholesterol with statins, ther...
BACKGROUND: Patients with evidence of vascular disease are at increased risk for subsequent vascular...
Background: Patients with evidence of vascular disease are at increased risk for subsequent vascular...
ObjectivesThis study sought to examine the relationship between niacin treatment, lipoproteins, and ...
Niacin has been used for more than 50 years in the treatment of cardiovascular disease, although its...
Contains fulltext : 142812.pdf (publisher's version ) (Open Access)OBJECTIVE: Niac...
International audienceBACKGROUND: Niacin as an adjunct to statin treatment to reduce cardiovascular ...
Niacin potently lowers triglycerides, mildly decreases LDL-cholesterol, and largely increases HDL-ch...
BACKGROUND Patients with evidence of vascular disease are at increased risk for subsequent vascular ...
Objective: Previous studies have suggested that niacin treatment raises glucose levels in patients w...
Item does not contain fulltextBACKGROUND AND AIM: High density lipoproteins (HDL) have been addresse...